APA (7th ed.) Citation

Supreeda Tambunlertchai, Sean M. Geary, & Aliasger K. Salem. (2022). Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. MDPI AG.

Chicago Style (17th ed.) Citation

Supreeda Tambunlertchai, Sean M. Geary, and Aliasger K. Salem. Topically Applied Resiquimod Versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. MDPI AG, 2022.

MLA (9th ed.) Citation

Supreeda Tambunlertchai, et al. Topically Applied Resiquimod Versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. MDPI AG, 2022.

Warning: These citations may not always be 100% accurate.